DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Puzanov I, McArthur G, Gonzalez R. et al.
Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7).
J Transl Med 2014;
12: O7
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.